Problem

Bringing a drug to market is an unusually research-intensive, regulation-heavy process: Y Combinator characterizes it as consuming roughly 500,000 days of office work. Regulatory-affairs teams must determine what agencies such as the FDA and EMA expect, often by searching large bodies of guidance, prior decisions, and scientific material. The economic pain is measured in weeks of specialist labor and potentially delayed development; a Rhizome customer says research that once took weeks was completed immediately, while another says ten minutes replaced weeks of work.

The killer use case is answering high-stakes regulatory questions during product development, including developing a regulatory strategy, designing a clinical trial, and preparing for agency interactions. Rhizome illustrates this with a Phase 1 oncology-trial question requiring alignment with both FDA and EMA expectations.

Product / Service

Rhizome Ask is a life-sciences research agent positioned as a hallucination-free regulatory coworker. A user asks a question, and the system searches health-authority databases, reads up to 1,000 documents, produces an answer in which each statement has a citation, and can turn the research into a briefing document. Its differentiation is a life-science-specific retrieval engine intended to find regulatory material that general-purpose search or AI systems miss.

The delivery model is software-as-a-service with a free tier, paid individual and project plans, a business plan with multiple seats and office hours, and a custom enterprise tier that adds non-English health-authority databases and security requirements. The benefit is to compress regulatory research from days or weeks into minutes while preserving source traceability for professional review.

Market

Rhizome competes in AI-enabled regulatory intelligence and research software for pharmaceutical, biotech, medical-device, and broader life-sciences organizations. The competitive landscape includes established regulatory-intelligence platforms such as Clarivate’s Cortellis Regulatory Intelligence, alongside overlapping regulatory and quality systems and tools such as Veeva Vault, Freyr, and other AI-based regulatory applications. Rhizome’s positioning is narrower and more agentic: it emphasizes cited deep research and direct answers to regulatory questions rather than serving only as a compliance repository or workflow system.

The company is an early commercial-stage startup rather than an unlaunched concept. Its site reports 20-plus customers, more than 2,800 answers, and usage by large pharmaceutical companies, independent consultants, and other life-sciences teams; LinkedIn describes dozens of organizations using it for regulatory strategy and clinical-trial design. It is listed by Y Combinator as an active Winter 2026 company, and its public site shows paid plans, but the reviewed materials do not disclose revenue or a funding amount, so the scale of commercialization remains difficult to quantify.